ENANTA PHARMACEUTICALS INC's ticker is ENTA and the CUSIP is 29251M106. A total of 173 filers reported holding ENANTA PHARMACEUTICALS INC in Q3 2020. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2021 | $0 | – | 0 | – | 0.00% | – |
Q1 2021 | $0 | – | 0 | – | 0.00% | – |
Q4 2020 | $0 | -100.0% | 0 | -100.0% | 0.00% | -100.0% |
Q3 2020 | $11,000 | – | 259 | – | 0.00% | – |
Q2 2020 | $0 | – | 0 | – | 0.00% | – |
Q1 2020 | $0 | – | 0 | – | 0.00% | – |
Q4 2019 | $0 | – | 0 | – | 0.00% | – |
Q3 2019 | $0 | -100.0% | 0 | -100.0% | 0.00% | – |
Q3 2018 | $12,000 | -25.0% | 136 | 0.0% | 0.00% | -100.0% |
Q2 2018 | $16,000 | +100.0% | 136 | 0.0% | 0.00% | – |
Q1 2018 | $8,000 | 0.0% | 136 | 0.0% | 0.00% | – |
Q4 2017 | $8,000 | +33.3% | 136 | 0.0% | 0.00% | – |
Q3 2017 | $6,000 | +20.0% | 136 | 0.0% | 0.00% | – |
Q2 2017 | $5,000 | +25.0% | 136 | 0.0% | 0.00% | – |
Q1 2017 | $4,000 | -60.0% | 136 | -56.3% | 0.00% | – |
Q4 2016 | $10,000 | +100.0% | 311 | +77.7% | 0.00% | – |
Q3 2016 | $5,000 | -86.1% | 175 | -89.4% | 0.00% | -100.0% |
Q2 2016 | $36,000 | -36.8% | 1,651 | -3.7% | 0.00% | -50.0% |
Q4 2015 | $57,000 | – | 1,714 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Krensavage Asset Management, LLC | 862,848 | $42,556,000 | 14.73% |
Fairmount Funds Management LLC | 171,147 | $8,441,000 | 3.56% |
ARMISTICE CAPITAL, LLC | 1,648,000 | $81,279,000 | 1.87% |
FARALLON CAPITAL MANAGEMENT LLC | 1,995,000 | $98,393,000 | 0.49% |
Jackson Creek Investment Advisors LLC | 21,409 | $1,056,000 | 0.37% |
Hennion & Walsh Asset Management, Inc. | 113,940 | $5,620,000 | 0.34% |
Virtus ETF Advisers LLC | 14,721 | $726,000 | 0.31% |
Granahan Investment Management | 193,416 | $9,539,000 | 0.20% |
Yorktown Management & Research Co Inc | 4,500 | $222,000 | 0.18% |
JACOBS LEVY EQUITY MANAGEMENT, INC | 242,257 | $11,948,000 | 0.09% |